


CLAIMS

1. A compound of Formula I including its stereoisomers, pharmaceutically
 5 acceptable salts, and hydrates thereof,



I

where:

X and Y are independently selected from halogen, hydroxymethyl, and
 10 acetoxyethyl;
 R¹ is selected from C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₇cycloalkyl,
 C₅₋₇cycloalkenyl, -(CH₂)₁₋₆CO₂R³, and -(CH₂)_n-;
 R² is selected from hydrogen, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkylcarbonyl, CONHR³,
 and ;
 15 R³ is selected from hydrogen and C₁₋₆alkyl;
 R⁴, R⁵, and R⁶ are independently selected from hydrogen, C₁₋₆alkyl, and C₁₋₆alkoxy;
 m is 0 or an integer from 1 to 6; and
 n is 0 or an integer from 1 to 6.

20 2. A compound of claim 1 wherein R³ is methyl, the carbon to which R³ is
 attached is of the (R) configuration, and m is 0.

3. A compound of claim 1 where R^1 is C_{1-6} alkyl, C_{3-6} alkenyl, or C_{3-6} alkynyl.
4. A compound of claim 2 where R^1 is C_{1-6} alkyl, C_{3-6} alkenyl, or C_{3-6} alkynyl.
5. A compound of claim 2 selected from the following group:
 - N-(2,5-dichlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexyn-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(4-hydroxy-1-hexen-5-yl)-4-chlorobenzenesulfonamide;
 - N-(2-fluoro-5-chlorophenyl)-N-(3-hydroxyhex-2-yl)-4-chlorobenzenesulfonamide; and
- 10 N-(2-hydroxymethyl-5-chlorophenyl)-N-(2-(N-3-(1-imidazolyl)prop-1-yl-carbamoyl)but-3-yl)-4-chlorobenzenesulfonamide.
- 15
6. A compound of claim 1 wherein R^3 is methyl, the carbon to which R^3 is attached is of the (R) configuration, and m is 1.
- 20
7. A pharmaceutical composition for the treatment of disorders responsive to the inhibition of β -amyloid peptide production wherein the composition comprises a therapeutically effective amount of a compound of claim 1 in association with a pharmaceutically acceptable carrier or diluent.
- 25
8. A pharmaceutical composition of claim 7 suitable for oral administration.
9. A method for the treatment of disorders responsive to the inhibition of β -amyloid peptide production in a mammal in need thereof, which comprises
- 30 administering to said mammal a therapeutically effective amount of a compound of claim 1.

10. A method of claim 9 wherein said disorder is Alzheimer's Disease and Down's Syndrome.